135 results on '"Djouadi, Fatima"'
Search Results
2. Wnt, glucocorticoid and cellular prion protein cooperate to drive a mesenchymal phenotype with poor prognosis in colon cancer
- Author
-
Mouillet-Richard, Sophie, Gougelet, Angélique, Passet, Bruno, Brochard, Camille, Le Corre, Delphine, Pitasi, Caterina Luana, Joubel, Camille, Sroussi, Marine, Gallois, Claire, Lavergne, Julien, Castille, Johan, Vilotte, Marthe, Daniel-Carlier, Nathalie, Pilati, Camilla, de Reyniès, Aurélien, Djouadi, Fatima, Colnot, Sabine, André, Thierry, Taieb, Julien, Vilotte, Jean-Luc, Romagnolo, Béatrice, and Laurent-Puig, Pierre
- Published
- 2024
- Full Text
- View/download PDF
3. Downregulation of mitochondrial complex I induces ROS production in colorectal cancer subtypes that differently controls migration
- Author
-
Bastin, Jean, Sroussi, Marine, Nemazanyy, Ivan, Laurent-Puig, Pierre, Mouillet-Richard, Sophie, and Djouadi, Fatima
- Published
- 2023
- Full Text
- View/download PDF
4. A proof of concept for targeting the PrPC - Amyloid β peptide interaction in basal prostate cancer and mesenchymal colon cancer
- Author
-
Mouillet-Richard, Sophie, Martin-Lannerée, Séverine, Le Corre, Delphine, Hirsch, Théo Z., Ghazi, Alexandre, Sroussi, Marine, Pilati, Camilla, de Reyniès, Aurélien, Djouadi, Fatima, Vodovar, Nicolas, Launay, Jean-Marie, and Laurent-Puig, Pierre
- Published
- 2022
- Full Text
- View/download PDF
5. Cellular prion protein dysfunction in a prototypical inherited metabolic myopathy
- Author
-
Boufroura, Fatima-Zohra, Tomkiewicz-Raulet, Céline, Poindessous, Virginie, Castille, Johan, Vilotte, Jean-Luc, Bastin, Jean, Mouillet-Richard, Sophie, and Djouadi, Fatima
- Published
- 2021
- Full Text
- View/download PDF
6. Inhibition of mitophagy drives macrophage activation and antibacterial defense during sepsis
- Author
-
Patoli, Danish, Mignotte, Franck, Deckert, Valerie, Dusuel, Alois, Dumont, Adelie, Rieu, Aurelie, Jalil, Antoine, Van Dongen, Kevin, Bourgeois, Thibaut, Gautier, Thomas, Magnani, Charlene, Guern, Naig Le, Mandard, Stephane, Bastin, Jean, Djouadi, Fatima, Schaeffer, Christine, Guillaumot, Nina, Narce, Michel, Nguyen, Maxime, Guy, Julien, Dargent, Auguste, Quenot, Jean-Pierre, Rialland, Mickael, Masson, David, Auwerx, Johan, Lagrost, Laurent, and Thomas, Charles
- Subjects
Macrophages -- Health aspects -- Physiological aspects ,Biological response modifiers -- Usage ,Autophagy (Cytology) -- Health aspects -- Physiological aspects ,Sepsis -- Development and progression -- Care and treatment ,Mitochondria -- Health aspects -- Physiological aspects ,Health care industry - Abstract
Mitochondria have emerged as key actors of innate and adaptive immunity. Mitophagy has a pivotal role in cell homeostasis, but its contribution to macrophage functions and host defense remains to be delineated. Here, we showed that lipopolysaccharide (LPS) in combination with IFN-[gamma] inhibited PINK1-dependent mitophagy in macrophages through a STAT1dependent activation of the inflammatory caspases 1 and 11. In addition, we demonstrated that the inhibition of mitophagy triggered classical macrophage activation in a mitochondrial ROS-dependent manner. In a murine model of polymicrobial infection (cecal ligature and puncture), adoptive transfer of Pink1-deficient bone marrow or pharmacological inhibition of mitophagy promoted macrophage activation, which favored bactericidal clearance and led to a better survival rate. Reciprocally, mitochondrial uncouplers that promote mitophagy reversed LPS/IFN-[gamma]-mediated activation of macrophages and led to immunoparalysis with impaired bacterial clearance and lowered survival. In critically ill patients, we showed that mitophagy was inhibited in blood monocytes of patients with sepsis as compared with nonseptic patients. Overall, this work demonstrates that the inhibition of mitophagy is a physiological mechanism that contributes to the activation of myeloid cells and improves the outcome of sepsis., Introduction Sepsis is one of the leading causes of morbidity and mortality in intensive care units (ICUs) (1). Strategies that blunt inflammatory responses have failed to improve survival, whereas those [...]
- Published
- 2020
- Full Text
- View/download PDF
7. The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer
- Author
-
Le Corre, Delphine, Ghazi, Alexandre, Balogoun, Ralyath, Pilati, Camilla, Aparicio, Thomas, Martin-Lannerée, Séverine, Marisa, Laetitia, Djouadi, Fatima, Poindessous, Virginie, Crozet, Carole, Emile, Jean-François, Mulot, Claire, Le Malicot, Karine, Boige, Valérie, Blons, Hélène, de Reynies, Aurélien, Taieb, Julien, Ghiringhelli, François, Bennouna, Jaafar, Launay, Jean-Marie, Laurent-Puig, Pierre, and Mouillet-Richard, Sophie
- Published
- 2019
- Full Text
- View/download PDF
8. The cellular prion protein is a stress protein secreted by renal tubular cells and a urinary marker of kidney injury
- Author
-
Bignon, Yohan, Poindessous, Virginie, Lazareth, Hélène, Passet, Bruno, Vilotte, Jean-Luc, Djouadi, Fatima, Mouillet-Richard, Sophie, and Pallet, Nicolas
- Published
- 2020
- Full Text
- View/download PDF
9. Mitochondrial trifunctional protein deficiency in human cultured fibroblasts: effects of bezafibrate
- Author
-
Djouadi, Fatima, Habarou, Florence, Le Bachelier, Carole, Ferdinandusse, Sacha, Schlemmer, Dimitri, Benoist, Jean François, Boutron, Audrey, Andresen, Brage S., Visser, Gepke, de Lonlay, Pascale, Olpin, Simon, Fukao, Toshiyuki, Yamaguchi, Seiji, Strauss, Arnold W., Wanders, Ronald J. A., and Bastin, Jean
- Published
- 2016
- Full Text
- View/download PDF
10. Loss of prion protein control of glucose metabolism promotes neurodegeneration in model of prion diseases
- Author
-
Arnould, Hélène, Baudouin, Vincent, Baudry, Anne, Ribeiro, Luiz W., Ardila-Osorio, Hector, Pietri, Mathéa, Caradeuc, Cédric, Soultawi, Cynthia, Williams, Declan, Alvarez, Marjorie, Crozet, Carole, Djouadi, Fatima, Laforge, Mireille, Bertho, Gildas, Kellermann, Odile, Launay, Jean-Marie, Schmitt-Ulms, Gerold, Schneider, Benoit, Toxicité environnementale, cibles thérapeutiques, signalisation cellulaire (T3S - UMR_S 1124), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques (LCBPT - UMR 8601), Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), University of Toronto, Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université de Paris (UP), Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP)-Université Sorbonne Paris Nord, Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), F. Hoffmann-La Roche [Basel], SCHNEIDER, Benoit, Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord
- Subjects
Male ,PrPSc Proteins ,animal diseases ,Biochemistry ,Hippocampus ,Prion Diseases ,Mice ,Medical Conditions ,Glucose Metabolism ,Animal Cells ,Zoonoses ,Medicine and Health Sciences ,Biology (General) ,[SDV.BBM.BC] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biochemistry [q-bio.BM] ,Energy-Producing Organelles ,Neurons ,Organic Compounds ,Monosaccharides ,Fatty Acids ,Brain ,Ketones ,Lipids ,Mitochondria ,Chemistry ,Infectious Diseases ,Physical Sciences ,Carbohydrate Metabolism ,[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] ,Cellular Structures and Organelles ,Cellular Types ,Anatomy ,Research Article ,Pyruvate ,QH301-705.5 ,Carbohydrates ,Bioenergetics ,mental disorders ,Animals ,[SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] ,[SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biochemistry [q-bio.BM] ,Organic Chemistry ,Chemical Compounds ,Biology and Life Sciences ,Cell Biology ,RC581-607 ,nervous system diseases ,Mice, Inbred C57BL ,Disease Models, Animal ,Oxidative Stress ,Metabolism ,Glucose ,Cellular Neuroscience ,Nerve Degeneration ,Immunologic diseases. Allergy ,Acids ,Protein Kinases ,Neuroscience - Abstract
Corruption of cellular prion protein (PrPC) function(s) at the plasma membrane of neurons is at the root of prion diseases, such as Creutzfeldt-Jakob disease and its variant in humans, and Bovine Spongiform Encephalopathies, better known as mad cow disease, in cattle. The roles exerted by PrPC, however, remain poorly elucidated. With the perspective to grasp the molecular pathways of neurodegeneration occurring in prion diseases, and to identify therapeutic targets, achieving a better understanding of PrPC roles is a priority. Based on global approaches that compare the proteome and metabolome of the PrPC expressing 1C11 neuronal stem cell line to those of PrPnull-1C11 cells stably repressed for PrPC expression, we here unravel that PrPC contributes to the regulation of the energetic metabolism by orienting cells towards mitochondrial oxidative degradation of glucose. Through its coupling to cAMP/protein kinase A signaling, PrPC tones down the expression of the pyruvate dehydrogenase kinase 4 (PDK4). Such an event favors the transfer of pyruvate into mitochondria and its conversion into acetyl-CoA by the pyruvate dehydrogenase complex and, thereby, limits fatty acids β-oxidation and subsequent onset of oxidative stress conditions. The corruption of PrPC metabolic role by pathogenic prions PrPSc causes in the mouse hippocampus an imbalance between glucose oxidative degradation and fatty acids β-oxidation in a PDK4-dependent manner. The inhibition of PDK4 extends the survival of prion-infected mice, supporting that PrPSc-induced deregulation of PDK4 activity and subsequent metabolic derangements contribute to prion diseases. Our study posits PDK4 as a potential therapeutic target to fight against prion diseases., Author summary Transmissible Spongiform Encephalopathies (TSEs), commonly named prion diseases, are caused by pathogenic prions PrPSc that trigger degeneration of neurons in the brain. Although PrPSc exerts its neurotoxicity by corrupting the function(s) of normal cellular prion protein (PrPC), our understanding of the mechanisms involved in prion diseases remains limited. There is still to date no medicine to fight against TSEs. The current study demonstrates that the deregulation of PrPC regulatory function towards glucose metabolism contributes to neurodegeneration in prion diseases. In the brain of prion-infected mice, PrPSc-induced overactivation of pyruvate dehydrogenase kinase 4 (PDK4) and downstream reduction in mitochondria pyruvate dehydrogenase (PDH) activity promote a metabolic shift from glucose oxidative degradation to pro-oxidant fatty acids β-oxidation contributing to prion pathogenesis. The pharmacological inhibition of PDK4 extends the lifespan of prion-infected mice by rescuing normal glucose metabolism. This study opens up new avenues to design PDK4-based therapeutic strategies to combat TSEs.
- Published
- 2021
11. Exploring new ways of regulation by resveratrol involving miRNAs, with emphasis on inflammation
- Author
-
Latruffe, Norbert, Lançon, Allan, Frazzi, Raffaele, Aires, Virginie, Delmas, Dominique, Michaille, Jean-Jacques, Djouadi, Fatima, Bastin, Jean, and Cherkaoui-Malki, Mustapha
- Published
- 2015
- Full Text
- View/download PDF
12. Prognostic value of the PrPC-ILK-IDO1 axis in the mesenchymal colorectal cancer subtype
- Author
-
Ghazi, Alexandre, Le Corre, Delphine, Pilati, Camilla, Taieb, Julien, Aparicio, Thomas, Didelot, Audrey, Dedhar, Shoukat, Mulot, Claire, Le Malicot, Karine, Djouadi, Fatima, De Reynies, Aurélien, Launay, Jean-Marie, Laurent-Puig, Pierre, Mouillet-Richard, Sophie, Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), BC Cancer Agency (BCCRC), Lipides - Nutrition - Cancer [Dijon - U1231] (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Ligue Nationale Contre le Cancer - Paris, Ligue Nationale Contre le Cancer (LNCC), Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, HAL-SU, Gestionnaire, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université de Paris (UP), Ligue Nationnale Contre le Cancer, and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP)-Université Sorbonne Paris Nord
- Subjects
integrin-linked kinase ,animal diseases ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology ,RC581-607 ,colorectal cancer molecular classification ,[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology ,nervous system diseases ,IDO ,Prion protein ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN] ,mental disorders ,[SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN] ,Immunologic diseases. Allergy ,Kynurenine pathway ,RC254-282 - Abstract
International audience; The CMS4 mesenchymal subtype of colorectal cancer (CRC) is associated with poor prognosis and resistance to treatment. The cellular prion protein PrP C is overexpressed in CMS4 tumors and controls the expression of a panel of CMS4-specific genes in CRC cell lines. Here, we sought to investigate PrP C downstream pathways that may underlie its role in CMS4 CRC. By combining gene set enrichment analyses and gain and loss of function approaches in CRC cell lines, we identify the integrin-linked kinase ILK as a proximal effector of PrP C that mediates its control on the CMS4 phenotype. We further leveraged three independent large CRC cohorts to assess correlations in gene expression pattern with patient outcomes and found that ILK is overexpressed in CMS4 mesenchymal tumors and confers a poor prognosis, especially when combined with high expression of the PrP C encoding gene PRNP. Of note, we discovered that the PrP C-ILK signaling axis controls the expression and activity of the tryptophan metabolizing enzyme indoleamine 2,3 dioxygenase IDO1, a key player in immune tolerance. In addition, we monitored alterations in the levels of tryptophan and its metabolites of the kynurenine pathway in the plasma of metastatic CRC patients (n = 325) and we highlight their prognostic value in combination with plasma PrP C levels. Thus, the PrP C-ILK-IDO1 axis plays a key role in the mesenchymal subtype of CRC. PrP C and IDO1-targeted strategies may represent new avenues for patient stratification and treatment in CRC.
- Published
- 2021
13. Beneficial effects of resveratrol on respiratory chain defects in patientsʼ fibroblasts involve estrogen receptor and estrogen-related receptor alpha signaling
- Author
-
Lopes Costa, Alexandra, Le Bachelier, Carole, Mathieu, Lise, Rotig, Agnès, Boneh, Avihu, De Lonlay, Pascale, Tarnopolsky, Mark A., Thorburn, David R., Bastin, Jean, and Djouadi, Fatima
- Published
- 2014
- Full Text
- View/download PDF
14. S6 Kinase Deletion Suppresses Muscle Growth Adaptations to Nutrient Availability by Activating AMP Kinase
- Author
-
Aguilar, Victor, Alliouachene, Samira, Sotiropoulos, Athanassia, Sobering, Andrew, Athea, Yoni, Djouadi, Fatima, Miraux, Sylvain, Thiaudière, Eric, Foretz, Marc, Viollet, Benoit, Diolez, Philippe, Bastin, Jean, Benit, Paule, Rustin, Pierre, Carling, David, Sandri, Marco, Ventura-Clapier, Renée, and Pende, Mario
- Published
- 2007
- Full Text
- View/download PDF
15. Organization of the human liver carnitine palmitoyltransferase 1 gene (CPT1A) and identification of novel mutations in hypoketotic hypoglycaemia
- Author
-
Gobin, Stéphanie, Bonnefont, Jean-Paul, Prip-Buus, Carina, Mugnier, Claude, Ferrec, Magali, Demaugre, France, Saudubray, Jean-Marie, Rostane, Hidayeth, Djouadi, Fatima, Wilcox, William, Cederbaum, Stephen, Haas, Richard, Nyhan, William L., Green, Anne, Gray, George, Girard, Jean, and Thuillier, Laure
- Published
- 2002
- Full Text
- View/download PDF
16. GSH monoethyl ester rescues mitochondrial defects in cystic fibrosis models
- Author
-
Kelly-Aubert, Mairead, Trudel, Stéphanie, Fritsch, Janine, Nguyen-Khoa, Thao, Baudouin-Legros, Maryvonne, Moriceau, Sandra, Jeanson, Ludovic, Djouadi, Fatima, Matar, Corine, Conti, Marc, Ollero, Mario, Brouillard, Franck, and Edelman, Aleksander
- Published
- 2011
- Full Text
- View/download PDF
17. Exposure to resveratrol triggers pharmacological correction of fatty acid utilization in human fatty acid oxidation-deficient fibroblasts
- Author
-
Bastin, Jean, Lopes-Costa, Alexandra, and Djouadi, Fatima
- Published
- 2011
- Full Text
- View/download PDF
18. Should the beneficial impact of bezafibrate on fatty acid oxidation disorders be questioned?
- Author
-
Bastin, Jean, Bonnefont, Jean-Paul, Djouadi, Fatima, and Bresson, Jean-Louis
- Published
- 2015
- Full Text
- View/download PDF
19. Bezafibrate for an Inborn Mitochondrial Beta-Oxidation Defect
- Author
-
Bonnefont, Jean-Paul, Bastin, Jean, Behin, Anthony, and Djouadi, Fatima
- Published
- 2009
- Full Text
- View/download PDF
20. Activation of Peroxisome Proliferator-Activated Receptor Pathway Stimulates the Mitochondrial Respiratory Chain and Can Correct Deficiencies in Patients’ Cells Lacking Its Components
- Author
-
Bastin, Jean, Aubey, Flore, Rötig, Agnès, Munnich, Arnold, and Djouadi, Fatima
- Published
- 2008
21. Mitochondrial Genetic Disorders: Cell Signaling and Pharmacological Therapies
- Author
-
Djouadi, Fatima, Bastin, Jean, Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Sorbonne Université (SU), Université Sorbonne Paris Cité (USPC), and Gestionnaire, Hal Sorbonne Université
- Subjects
AMPK ,Mitochondrial Diseases ,inborn mitochondrial disorders ,[SDV]Life Sciences [q-bio] ,Review ,PPAR ,ROS 1 Mitochondrial Energy Metabolism Disorders ,Electron Transport ,SIRT1 ,Animals ,Humans ,lcsh:QH301-705.5 ,BZ ,Genetic Diseases, Inborn ,RSV ,ROS ,NAD ,PGC-1alpha ,[SDV] Life Sciences [q-bio] ,lcsh:Biology (General) ,[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,Energy Metabolism ,Oxidation-Reduction ,pharmacological therapy ,Signal Transduction - Abstract
International audience; Mitochondrial fatty acid oxidation (FAO) and respiratory chain (RC) defects form a large group of inherited monogenic disorders sharing many common clinical and pathophysiological features, including disruption of mitochondrial bioenergetics, but also, for example, oxidative stress and accumulation of noxious metabolites. Interestingly, several transcription factors or co-activators exert transcriptional control on both FAO and RC genes, and can be activated by small molecules, opening to possibly common therapeutic approaches for FAO and RC deficiencies. Here, we review recent data on the potential of various drugs or small molecules targeting pivotal metabolic regulators: peroxisome proliferator activated receptors (PPARs), sirtuin 1 (SIRT1), AMP-activated protein kinase (AMPK), and protein kinase A (PKA)) or interacting with reactive oxygen species (ROS) signaling, to alleviate or to correct inborn FAO or RC deficiencies in cellular or animal models. The possible molecular mechanisms involved, in particular the contribution of mitochondrial biogenesis, are discussed. Applications of these pharmacological approaches as a function of genotype/phenotype are also addressed, which clearly orient toward personalized therapy. Finally, we propose that beyond the identification of individual candidate drugs/molecules, future pharmacological approaches should consider their combination, which could produce additive or synergistic effects that may further enhance their therapeutic potential. The inborn defects of mitochondrial fatty acid β-oxidation (FAO) and respiratory chain (RC) rank among the most frequent genetic disorders of energy metabolism in human [1]. Although both groups of diseases are often presented and discussed separately by clinicians and researchers, they share many common features. Among them: (i) both groups of disorders are caused by the partial or total loss of function of a single protein or enzyme essential to the mitochondrial RC or to the FAO pathway; (ii) a large number of disease-causing genes have been identified, and each individual disorder is generally associated with a wide panel of gene mutations, with poorly understood genotype-phenotype correlations; (iii) the pathogenesis of these diseases involves not only bioenergetics defects due to disruption of mitochondrial structure and function, but also multiple other mechanisms-including ROS overproduction, oxidative stress, and accumulation of noxious intermediates; (iv) these disorders are clinically heterogeneous and can manifest in neonates, children, or adults with very diverse symptoms affecting one or several organs with high energy demand-including heart, skeletal muscle, liver, and brain; and (v) most of these disorders remain without treatment to date. Most importantly, and as we will see in this review, the FAO pathway and mitochondrial RC can be regulated, directly or indirectly, by the same transcription factors or co-activators, which leads to eventually propose the
- Published
- 2019
22. Peroxisome Proliferator Activated Receptor δ (PPARδ) Agonist But Not PPARα Corrects Carnitine Palmitoyl Transferase 2 Deficiency in Human Muscle Cells
- Author
-
Djouadi, Fatima, Aubey, Flore, Schlemmer, Dimitri, and Bastin, Jean
- Published
- 2005
23. Human and preclinical studies of the host-gut microbiome co-metabolite hippurate as a marker and mediator of metabolic health.
- Author
-
Brial, François, Chilloux, Julien, Nielsen, Trine, Vieira-Silva, Sara, Falony, Gwen, Andrikopoulos, Petros, Olanipekun, Michael, Hoyles, Lesley, Djouadi, Fatima, Neves, Ana L., Rodriguez-Martinez, Andrea, Mouawad, Ghiwa Ishac, Pons, Nicolas, Forslund, Sofia, Le-chatelier, Emmanuelle, Le Lay, Aurélie, Nicholson, Jeremy, Hansen, Torben, Hyötyläinen, Tuulia, and Clément, Karine
- Subjects
SHOTGUN sequencing ,LOW-fat diet ,TYPE 2 diabetes ,BOTANY ,BIOTIC communities ,COMPUTATIONAL biology ,MEDICAL sciences ,LOCUS (Genetics) - Published
- 2021
- Full Text
- View/download PDF
24. PPARα Gene Expression in the Developing Rat Kidney: Role of Glucocorticoids
- Author
-
DJOUADI, FATIMA and BASTIN, JEAN
- Published
- 2001
25. A Gender-related Defect in Lipid Metabolism and Glucose Homeostasis in Peroxisome Proliferator-activated Receptor [small alpha, Greek]-deficient Mice
- Author
-
Djouadi, Fatima, Weinheimer, Carla J., Saffitz, Jeffrey E., Pitchford, Clovis, Bastin, Jean, Gonzalez, Frank J., and Kelly, Daniel P.
- Published
- 1998
26. Monoamine oxidase in developing rat renal cortex: effect of dexamethasone treatment
- Author
-
Bompart, Guy, Copin, Nane, Djouadi, Fatima, Bastin, Jean, Ordener, Catherine, and Parini, Angelo
- Published
- 2001
- Full Text
- View/download PDF
27. Prognostic value of the PrPC-ILK-IDO1 axis in the mesenchymal colorectal cancer subtype.
- Author
-
Ghazi, Alexandre, Le Corre, Delphine, Pilati, Camilla, Taieb, Julien, Aparicio, Thomas, Didelot, Audrey, Dedhar, Shoukat, Mulot, Claire, Le Malicot, Karine, Djouadi, Fatima, de Reynies, Aurélien, Launay, Jean-Marie, Laurent-Puig, Pierre, and Mouillet-Richard, Sophie
- Subjects
PROGNOSIS ,COLORECTAL cancer ,IMMUNOLOGICAL tolerance ,DIOXYGENASES ,GENE expression ,CELL lines ,TUMOR suppressor proteins - Abstract
The CMS4 mesenchymal subtype of colorectal cancer (CRC) is associated with poor prognosis and resistance to treatment. The cellular prion protein PrP
C is overexpressed in CMS4 tumors and controls the expression of a panel of CMS4-specific genes in CRC cell lines. Here, we sought to investigate PrPC downstream pathways that may underlie its role in CMS4 CRC. By combining gene set enrichment analyses and gain and loss of function approaches in CRC cell lines, we identify the integrin-linked kinase ILK as a proximal effector of PrPC that mediates its control on the CMS4 phenotype. We further leveraged three independent large CRC cohorts to assess correlations in gene expression pattern with patient outcomes and found that ILK is overexpressed in CMS4 mesenchymal tumors and confers a poor prognosis, especially when combined with high expression of the PrPC encoding gene PRNP. Of note, we discovered that the PrPC -ILK signaling axis controls the expression and activity of the tryptophan metabolizing enzyme indoleamine 2,3 dioxygenase IDO1, a key player in immune tolerance. In addition, we monitored alterations in the levels of tryptophan and its metabolites of the kynurenine pathway in the plasma of metastatic CRC patients (n = 325) and we highlight their prognostic value in combination with plasma PrPC levels. Thus, the PrPC-ILK-IDO1 axis plays a key role in the mesenchymal subtype of CRC. PrPC and IDO1-targeted strategies may represent new avenues for patient stratification and treatment in CRC. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
28. Low-Intensity Running and High-Intensity Swimming Exercises Differentially Improve Energy Metabolism in Mice With Mild Spinal Muscular Atrophy.
- Author
-
Houdebine, Léo, D'Amico, Domenico, Bastin, Jean, Chali, Farah, Desseille, Céline, Rumeau, Valentin, Soukkari, Judy, Oudot, Carole, Rouquet, Thaïs, Bariohay, Bruno, Roux, Julien, Sapaly, Delphine, Weill, Laure, Lopes, Philippe, Djouadi, Fatima, Bezier, Cynthia, Charbonnier, Frédéric, and Biondi, Olivier
- Subjects
SPINAL muscular atrophy ,AEROBIC capacity ,RESPIRATORY muscles ,ENERGY metabolism ,ANAEROBIC capacity ,OXYGEN consumption ,SWIMMING - Abstract
Spinal Muscular Atrophy (SMA), an autosomal recessive neurodegenerative disease characterized by the loss of spinal-cord motor-neurons, is caused by mutations on Survival-of-Motor Neuron (SMN)-1 gene. The expression of SMN 2, a SMN1 gene copy, partially compensates for SMN1 disruption due to exon-7 excision in 90% of transcripts subsequently explaining the strong clinical heterogeneity. Several alterations in energy metabolism, like glucose intolerance and hyperlipidemia, have been reported in SMA at both systemic and cellular level, prompting questions about the potential role of energy homeostasis and/or production involvement in disease progression. In this context, we have recently reported the tolerance of mild SMA-like mice (Smn
Δ7/Δ7 ; huSMN2+/+ ) to 10 months of low-intensity running or high-intensity swimming exercise programs, respectively involving aerobic and a mix aerobic/anaerobic muscular metabolic pathways. Here, we investigated whether those exercise-induced benefits were associated with an improvement in metabolic status in mild SMA-like mice. We showed that untrained SMA-like mice exhibited a dysregulation of lipid metabolism with an enhancement of lipogenesis and adipocyte deposits when compared to control mice. Moreover, they displayed a high oxygen consumption and energy expenditure through β-oxidation increase yet for the same levels of spontaneous activity. Interestingly, both exercises significantly improved lipid metabolism and glucose homeostasis in SMA-like mice, and enhanced oxygen consumption efficiency with the maintenance of a high oxygen consumption for higher levels of spontaneous activity. Surprisingly, more significant effects were obtained with the high-intensity swimming protocol with the maintenance of high lipid oxidation. Finally, when combining electron microscopy, respiratory chain complexes expression and enzymatic activity measurements in muscle mitochondria, we found that (1) a muscle-specific decreased in enzymatic activity of respiratory chain I, II, and IV complexes for equal amount of mitochondria and complexes expression and (2) a significant decline in mitochondrial maximal oxygen consumption, were reduced by both exercise programs. Most of the beneficial effects were obtained with the high-intensity swimming protocol. Taking together, our data support the hypothesis that active physical exercise, including high-intensity protocols, induces metabolic adaptations at both systemic and cellular levels, providing further evidence for its use in association with SMN-overexpressing therapies, in the long-term care of SMA patients. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
29. A potential link between PPAR signaling and the pathogenesis of arrhythmogenic right ventricular cardiomyopathy (ARVC) Time for Primary review: 50 Days Cardiovascular Research Advance
- Author
-
Djouadi, Fatima, Lecarpentier, Yves, Hebert, Jean-Louis, Charron, Philippe, Bastin, Jean, Coirault, Catherine, Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Service d'Explorations Fonctionnelles Cardio-Respiratoires, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital de Bicêtre, CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Thérapie des maladies du muscle strié, Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), École Pratique des Hautes Études (EPHE), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Djouadi, Fatima
- Subjects
[SDV] Life Sciences [q-bio] ,[SDV]Life Sciences [q-bio] ,ComputingMilieux_MISCELLANEOUS - Abstract
International audience
- Published
- 2009
30. Resveratrol-Induced Changes in MicroRNA Expression in Primary Human Fibroblasts Harboring Carnitine-Palmitoyl Transferase-2 Gene Mutation, Leading to Fatty Acid Oxidation Deficiency.
- Author
-
Aires, Virginie, Delmas, Dominique, Djouadi, Fatima, Bastin, Jean, Cherkaoui-Malki, Mustapha, and Latruffe, Norbert
- Subjects
CARNITINE palmitoyltransferase ,MICRORNA ,GENE expression ,FIBROBLASTS ,RESVERATROL ,FATTY acid oxidation - Abstract
Carnitine palmitoyltransferase-2 (CPT2) is a mitochondrial enzyme involved in long-chain fatty acid entry into mitochondria for their β-oxidation and energy production. Two phenotypes are associated with the extremely reduced CPT2 activity in genetically deficient patients: neonatal lethality or, in milder forms, myopathy. Resveratrol (RSV) is a phytophenol produced by grape plant in response to biotic or abiotic stresses that displays anti-oxidant properties, in particular through AP-1, NFκ B, STAT-3, and COX pathways. Some beneficiary effects of RSV are due to its modulation of microRNA (miRNA) expression. RSV can enhance residual CPT2 activities in human fibroblasts derived from CPT2-deficient patients and restores normal fatty acid oxidation rates likely through stimulation of mitochondrial biogenesis. Here, we report changes in miRNA expression linked to CPT2-deficiency, and we identify miRNAs whose expression changed following RSV treatment of control or CPT2-deficient fibroblasts isolated from patients. Our findings suggest that RSV consumption might exert beneficiary effects in patients with CPT2-deficiency. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
31. Specific Physical Exercise Improves Energetic Metabolism in the Skeletal Muscle of Amyotrophic-Lateral- Sclerosis Mice.
- Author
-
Desseille, Céline, Deforges, Séverine, Biondi, Olivier, Houdebine, Léo, D'amico, Domenico, Lamazière, Antonin, Caradeuc, Cédric, Bertho, Gildas, Bruneteau, Gaëlle, Weill, Laure, Bastin, Jean, Djouadi, Fatima, Salachas, François, Lopes, Philippe, Chanoine, Christophe, Massaad, Charbel, and Charbonnier, Frédéric
- Subjects
AMYOTROPHIC lateral sclerosis treatment ,EXERCISE ,LIPID transfer protein - Abstract
Amyotrophic Lateral Sclerosis is an adult-onset neurodegenerative disease characterized by the specific loss of motor neurons, leading to muscle paralysis and death. Although the cellular mechanisms underlying amyotrophic lateral sclerosis (ALS)-induced toxicity for motor neurons remain poorly understood, growing evidence suggest a defective energetic metabolism in skeletal muscles participating in ALS-induced motor neuron death ultimately destabilizing neuromuscular junctions. In the present study, we report that a specific exercise paradigm, based on a high intensity and amplitude swimming exercise, significantly improves glucose metabolism in ALS mice. Using physiological tests and a biophysics approach based on nuclear magnetic resonance (NMR), we unexpectedly found that SOD1(G93A) ALS mice suffered from severe glucose intolerance, which was counteracted by high intensity swimming but not moderate intensity running exercise. Furthermore, swimming exercise restored the highly ALS-sensitive tibialis muscle through an autophagy-linked mechanism involving the expression of key glucose transporters and metabolic enzymes, including GLUT4 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Importantly, GLUT4 and GAPDH expression defects were also found in muscles from ALS patients. Moreover, we report that swimming exercise induced a triglyceride accumulation in ALS tibialis, likely resulting from an increase in the expression levels of lipid transporters and biosynthesis enzymes, notably DGAT1 and related proteins. All these data provide the first molecular basis for the differential effects of specific exercise type and intensity in ALS, calling for the use of physical exercise as an appropriate intervention to alleviate symptoms in this debilitating disease. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
32. Resveratrol and Myopathy.
- Author
-
Bastin, Jean and Djouadi, Fatima
- Abstract
Resveratrol is a natural polyphenolic compound produced by plants under various stress conditions. Resveratrol has been reported to exhibit antioxidant, anti-inflammatory, and anti-proliferative properties in mammalian cells and animal models, and might therefore exert pleiotropic beneficial effects in different pathophysiological states. More recently, resveratrol has also been shown to potentially target many mitochondrial metabolic pathways, including fatty acid β-oxidation or oxidative phosphorylation, leading to the up-regulation of the energy metabolism via signaling pathways involving PGC-1α, SIRT1, and/or AMP-kinase, which are not yet fully delineated. Some of resveratrol beneficial effects likely arise from its cellular effects in the skeletal muscle, which, surprisingly, has been given relatively little attention, compared to other target tissues. Here, we review the potential for resveratrol to ameliorate or correct mitochondrial metabolic deficiencies responsible for myopathies, due to inherited fatty acid β-oxidation or to respiratory chain defects, for which no treatment exists to date. We also review recent data supporting therapeutic effects of resveratrol in the Duchenne Muscular Dystrophy, a fatal genetic disease affecting the production of muscle dystrophin, associated to a variety of mitochondrial dysfunctions, which likely contribute to disease pathogenesis. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
33. Stilbenes and resveratrol metabolites improve mitochondrial fatty acid oxidation defects in human fibroblasts.
- Author
-
Aires, Virginie, Delmas, Dominique, Bachelier, Carole Le, Latruffe, Norbert, Schlemmer, Dimitri, Benoist, Jean-François, Djouadi, Fatima, and Bastin, Jean
- Subjects
STILBENE ,RESVERATROL ,FATTY acid oxidation ,FATTY acid oxidation disorders ,FIBROBLASTS - Abstract
Background Inborn enzyme defects of mitochondrial fatty acid beta-oxidation (FAO) form a large group of genetic disorders associated to variable clinical presentations ranging from life-threatening pediatric manifestations up to milder late onset phenotypes, including myopathy. Very few candidate drugs have been identified in this group of disorders. Resveratrol (RSV) is a natural polyphenol with anti-oxidant and anti-inflammatory effects, recently shown to have beneficial metabolic properties in mice models. Our study explores its possible effects on FAO and mitochondrial energy metabolism in human cells, which are still very little documented. Methods Using cells from controls and from patients with Carnitine Palmitoyl Transferase 2 (CPT2) or Very Long Chain AcylCoA Dehydrogenase (VLCAD) deficiency we characterized the metabolic effects of RSV, RSV metabolites, and other stilbenes. We also focused on analysis of RSV uptake, and on the effects of low RSV concentrations, considering the limited bioavailability of RSV in vivo. Results Time course of RSV accumulation in fibroblasts over 48 h of treatment were consistent with the resulting stimulation or correction of FAO capacities. At 48 h, half maximal and maximal FAO stimulations were respectively achieved for 37,5 microM (EC50) and 75 microM RSV, but we found that serum content of culture medium negatively modulated RSV uptake and FAO induction. Indeed, decreasing serum from 12% to 3% led to shift EC50 from 37,5 to 13 microM, and a 2.6-3.6-fold FAO stimulation was reached with 20 microM RSV at 3% serum, that was absent at 12% serum. Two other stilbenes often found associated with RSV, i.e. cis- RSV and piceid, also triggered significant FAO up-regulation. Resveratrol glucuro- or sulfoconjugates had modest or no effects. In contrast, dihydro-RSV, one of the most abundant circulating RSV metabolites in human significantly stimulated FAO (1.3-2.3-fold). Conclusions This study provides the first compared data on mitochondrial effects of resveratrol, its metabolites, and other natural compounds of the stilbene family in human cells. The results clearly indicate that several of these compounds can improve mitochondrial FAO capacities in human FAO-deficient cells. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
34. A potential link between peroxisome proliferator-activated receptor signalling and the pathogenesis of arrhythmogenic right ventricular cardiomyopathy.
- Author
-
Djouadi, Fatima, Lecarpentier, Yves, Hébert, Jean-Louis, Charron, Philippe, Bastin, Jean, and Coirault, Catherine
- Subjects
- *
PEROXISOMES , *ARRHYTHMIA , *RIGHT heart ventricle , *CARDIOMYOPATHIES , *HEART failure - Abstract
Aims: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is characterized by major fibro-fatty replacement of the right ventricle (RV). We hypothesized that changes in peroxisome proliferator-activated receptor (PPAR) signalling contributed to myocardium fatty accumulation and contractile dysfunction in ARVC. [ABSTRACT FROM PUBLISHER]
- Published
- 2009
- Full Text
- View/download PDF
35. Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects
- Author
-
Bonnefont, Jean-Paul, Djouadi, Fatima, Prip-Buus, Carina, Gobin, Stephanie, Munnich, Arnold, and Bastin, Jean
- Subjects
- *
VITAMIN B complex , *CARNITINE , *PROTEINS , *BIOMOLECULES - Abstract
Carnitine palmitoyltransferase (CPT) deficiencies are common disorders of mitochondrial fatty acid oxidation. The CPT system is made up of two separate proteins located in the outer (CPT1) and inner (CPT2) mitochondrial membranes. While CPT2 is an ubiquitous protein, three tissue-specific CPT1 isoforms––the so-called “liver” (CPT1-A), “muscle” (CPT1B) and
‹ brain› (CPT1-C) CPT1s––have been shown to exist. Amino acid and cDNA nucleotide sequences have been identified for all of these proteins. CPT1-A deficiency presents as recurrent attacks of fasting hypoketotic hypoglycemia. Twenty four CPT1A mutations have been reported to date. CPT1-B and -C deficiencies have not been hitherto identified. CPT2 deficiency has several clinical presentations. The “benign” adult form (more than 200 families reported) is characterized by episodes of rhabdomyolysis triggered by prolonged exercise. The prevalent S113L mutation is found in about 50% of mutant alleles. The infantile-type CPT2 presents as severe attacks of hypoketotic hypoglycemia, occasionally associated with cardiac damage commonly responsible for sudden death before 1 year of age. In addition to these symptoms, features of brain and kidney dysorganogenesis are frequently seen in the neonatal-onset CPT2 deficiency, almost always lethal during the first month of life. Around 40 CPT2 mutations (private missense or truncating mutations) have hitherto been detected. Treatment is based upon avoidance of fasting and/or exercise, a low fat diet enriched with medium chain triglycerides and carnitine. Prenatal diagnosis may be offered for pregnancies at a 1/4 risk of infantile/severe-type CPT2 deficiency. [Copyright &y& Elsevier]- Published
- 2004
- Full Text
- View/download PDF
36. Characterization of fatty acid oxidation in human muscle mitochondria and myoblasts
- Author
-
Djouadi, Fatima, Bonnefont, Jean-Paul, Munnich, Arnold, and Bastin, Jean
- Subjects
- *
FATTY acids , *MITOCHONDRIA - Abstract
The mitochondrial oxidation of fatty acids (FAO) is the main energy-producing pathway in skeletal and cardiac muscle. Starting from standard muscle biopsies (100–200 mg), we determined the optimal conditions of mitochondrial oxygen consumption by the FAO pathway, and in parallel we performed the isolation and primary culture of muscle cells to test their cellular FAO capacities. The determinations of maximal β-oxidation rates in the presence of palmitoyl-CoA or palmitoyl-l-carnitine (mean ± SEM:
32.5±2.0 and34.1±1.3 nmol O2 min−1 mg−1 protein,n=16 , respectively) provide a screening method of mitochondrial fatty acid transport system and intra-mitochondrial β-oxidation. We also determined the conditions of tritiated palmitate oxidation by human myoblasts (mean ± SEM:6.6±0.1 nmol 3H fatty acid h−1 mg−1 protein,n=8 ), and show that β-oxidation defects can be detected in our experiments. Overall, we propose an original laboratory test to investigate FAO in human skeletal muscle and to screen for FAO disorders in myopathies and cardiomyopathies in human. [Copyright &y& Elsevier]- Published
- 2003
- Full Text
- View/download PDF
37. Effects of fatty acids on mitochondrial Β-oxidation enzyme gene expression in renal cell lines.
- Author
-
Quali, Fetta, Djouadi, Fatima, and Bastin, Jean
- Subjects
- *
FATTY acids , *GENE expression , *CELL lines , *KIDNEYS - Abstract
Examines the effects of fatty acids on mitochondrial Beta–oxidation enzyme gene expression in renal cell lines. Effect of fatty acids on gene expression of medium-chain acyl-CoA dehydrogenase; Occurrence of fatty acid-induced gene stimulation in the absence of cellular fatty acid accumulation; Development of fatty acid utilization in the kidney.
- Published
- 2002
38. Species Differences in the Effects of Bezafibrate as a Potential Treatment of Mitochondrial Disorders
- Author
-
Djouadi, Fatima and Bastin, Jean
- Published
- 2011
- Full Text
- View/download PDF
39. Mitochondrial Fatty Acid β-Oxidation and Resveratrol Effect in Fibroblasts from Patients with Autism Spectrum Disorder.
- Author
-
Barone, Rita, Bastin, Jean, Djouadi, Fatima, Singh, Indrapal, Karim, Mohammad Azharul, Ammanamanchi, Amrit, McCarty, Patrick John, Delhey, Leanna, Shannon, Rose, Casabona, Antonino, Rizzo, Renata, and Frye, Richard Eugene
- Subjects
AUTISM spectrum disorders ,AUTISTIC people ,FATTY acids ,FIBROBLASTS ,RESVERATROL ,MITOCHONDRIA - Abstract
Patients with autism spectrum disorder (ASD) may have an increase in blood acyl-carnitine (AC) concentrations indicating a mitochondrial fatty acid β-oxidation (mtFAO) impairment. However, there are no data on systematic mtFAO analyses in ASD. We analyzed tritiated palmitate oxidation rates in fibroblasts from patients with ASD before and after resveratrol (RSV) treatment, according to methods used for the diagnosis of congenital defects in mtFAO. ASD participants (N = 10, 60%; male; mean age (SD) 7.4 (3.2) years) were divided in two age-equivalent groups based on the presence (N = 5) or absence (N = 5) of elevated blood AC levels. In addition, electron transport chain (ETC) activity in fibroblasts and muscle biopsies and clinical characteristics were compared between the ASD groups. Baseline fibroblast mtFAO was not significantly different in patients in comparison with control values. However, ASD patients with elevated AC exhibited significantly decreased mtFAO rates, muscle ETC complex II activity, and fibroblast ETC Complex II/III activity (p < 0.05), compared with patients without an AC signature. RSV significantly increased the mtFAO activity in all study groups (p = 0.001). The highest mtFAO changes in response to RSV were observed in fibroblasts from patients with more severe symptoms on the Social Responsiveness Scale total (p = 0.001) and Awareness, Cognition, Communication and Motivation subscales (all p < 0.01). These findings suggested recognition of an ASD patient subset characterized by an impaired mtFAO flux associated with abnormal blood AC. The study elucidated that RSV significantly increased fibroblast mtFAO irrespective of plasma AC status, and the highest changes to RSV effects on mtFAO were observed in the more severely affected patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
40. Thromboxane synthase mutations in an increased bone density disorder (Ghosal syndrome).
- Author
-
Geneviève, David, Proulle, Valérie, Isidor, Bertrand, Bellais, Samuel, Serre, Valérie, Djouadi, Fatima, Picard, Capucine, Vignon-Savoye, Capucine, Bader-Meunier, Brigitte, Blanche, Stéphane, de Vernejoul, Marie-Christine, Legeai-Mallet, Laurence, Fischer, Anne-Marie, Le Merrer, Martine, Dreyfus, Marie, Gaussem, Pascale, Munnich, Arnold, and Cormier-Daire, Valérie
- Subjects
DYSPLASIA ,GENETIC disorders ,BONE density ,THROMBOXANES ,GENETIC mutation - Abstract
Studying consanguineous families with Ghosal hematodiaphyseal dysplasia syndrome (GHDD), a disorder of increased bone density, we identified mutations in TBXAS1, which encodes thromboxane synthase (TXAS). TXAS, an enzyme of the arachidonic acid cascade, produces thromboxane A
2 (TXA2 ). Platelets from subjects with GHDD showed a specific deficit in arachidonic acid–produced aggregation. We also found that TXAS and TXA2 modulated expression of TNFSF11 and TNFRSF11B (encoding RANKL and osteoprotegerin (OPG), respectively) in primary cultured osteoblasts. [ABSTRACT FROM AUTHOR]- Published
- 2008
- Full Text
- View/download PDF
41. Compared effects of missense mutations in Very-Long-Chain Acyl-CoA Dehydrogenase deficiency: Combined analysis by structural, functional and pharmacological approaches
- Author
-
Gobin-Limballe, Stéphanie, McAndrew, Ryan P., Djouadi, Fatima, Kim, Jung-Ja, and Bastin, Jean
- Subjects
- *
GENETIC mutation , *PHENOTYPES , *CARDIOMYOPATHIES , *DEHYDROGENASES , *AMINO acids , *OXIDATION , *STRUCTURE-activity relationships , *DISEASE management - Abstract
Abstract: Very-Long-Chain Acyl-CoA Dehydrogenase deficiency (VLCADD) is an autosomal recessive disorder considered as one of the more common ß-oxidation defects, possibly associated with neonatal cardiomyopathy, infantile hepatic coma, or adult-onset myopathy. Numerous gene missense mutations have been described in these VLCADD phenotypes, but only few of them have been structurally and functionally analyzed, and the molecular basis of disease variability is still poorly understood. To address this question, we first analyzed fourteen disease-causing amino acid changes using the recently described crystal structure of VLCAD. The predicted effects varied from the replacement of amino acid residues lining the substrate binding cavity, involved in holoenzyme–FAD interactions or in enzyme dimerisation, predicted to have severe functional consequences, up to amino acid substitutions outside key enzyme domains or lying on near enzyme surface, with predicted milder consequences. These data were combined with functional analysis of residual fatty acid oxidation (FAO) and VLCAD protein levels in patient cells harboring these mutations, before and after pharmacological stimulation by bezafibrate. Mutations identified as detrimental to the protein structure in the 3-D model were generally associated to profound FAO and VLCAD protein deficiencies in the patient cells, however, some mutations affecting FAD binding or monomer–monomer interactions allowed a partial response to bezafibrate. On the other hand, bezafibrate restored near-normal FAO rates in some mutations predicted to have milder consequences on enzyme structure. Overall, combination of structural, biochemical, and pharmacological analysis allowed assessment of the relative severity of individual mutations, with possible applications for disease management and therapeutic approach. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
42. Next generation sequencing of RNA reveals novel targets of resveratrol with possible implications for Canavan disease.
- Author
-
Dembic, Maja, Andersen, Henriette S., Bastin, Jean, Doktor, Thomas K., Corydon, Thomas J., Sass, Jörn Oliver, Costa, Alexandra Lopes, Djouadi, Fatima, and Andresen, Brage S.
- Subjects
- *
RESVERATROL , *FIBROBLASTS , *CANAVAN disease , *ADENYLATE cyclase , *VITAMIN B2 - Abstract
Abstract Resveratrol (RSV) is a small compound first identified as an activator of sirtuin 1 (SIRT1), a key factor in mediating the effects of caloric restriction. Since then, RSV received great attention for its widespread beneficial effects on health and in connection to many diseases. RSV improves the metabolism and the mitochondrial function, and more recently it was shown to restore fatty acid β-oxidation (FAO) capacities in patient fibroblasts harboring mutations with residual enzyme activity. Many of RSV's beneficial effects are mediated by the transcriptional coactivator PGC-1α, a direct target of SIRT1 and a master regulator of the mitochondrial fatty acid oxidation. Despite numerous studies RSV's mechanism of action is still not completely elucidated. Our aim was to investigate the effects of RSV on gene regulation on a wide scale, possibly to detect novel genes whose up-regulation by RSV may be of interest with respect to disease treatment. We performed Next Generation Sequencing of RNA on normal fibroblasts treated with RSV. To investigate whether the effects of RSV are mediated through SIRT1 we expanded the analysis to include SIRT1-knockdown fibroblasts. We identified the aspartoacylase (ASPA) gene, mutated in Canavan disease, to be strongly up-regulated by RSV in several cell lines, including Canavan disease fibroblasts. We further link RSV to the up-regulation of other genes involved in myelination including the glial specific transcription factors POU3F1 , POU3F2 , and myelin basic protein (MBP). We also observe a strong up-regulation by RSV of the riboflavin transporter gene SLC52a1. Mutations in SLC52a1 cause transient multiple acyl-CoA dehydrogenase deficiency (MADD). Our analysis of alternative splicing identified novel metabolically important genes affected by RSV, among which is particularly interesting the α subunit of the stimulatory G protein (Gsα), which regulates the cellular levels of cAMP through adenylyl cyclase. We conclude that in fibroblasts RSV stimulates the PGC-1α and p53 pathways, and up-regulates genes affecting the glucose metabolism, mitochondrial β-oxidation, and mitochondrial biogenesis. We further confirm that RSV might be a relevant treatment in the correction of FAO deficiencies and we suggest that treatment in other metabolic disorders including Canavan disease and MADD might be also beneficial. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
43. Resveratrol attenuates oxidative stress in mitochondrial Complex I deficiency: Involvement of SIRT3.
- Author
-
Mathieu, Lise, Costa, Alexandra Lopes, Le Bachelier, Carole, Slama, Abdelhamid, Lebre, Anne-Sophie, Taylor, Robert W., Bastin, Jean, and Djouadi, Fatima
- Subjects
- *
MITOCHONDRIAL pathology , *RESVERATROL , *PATHOLOGICAL physiology , *OXIDATIVE stress , *POLYPHENOLS , *DRUG efficacy , *THERAPEUTICS - Abstract
The pathophysiological mechanisms underlying Complex I (CI) deficiencies are understood only partially which severely limits the treatment of this common, devastating, mitochondrial disorder. Recently, we have shown that resveratrol (RSV), a natural polyphenol, has beneficial effects on CI deficiency of nuclear origin. Here, we demonstrate that RSV is able to correct the biochemical defect in oxygen consumption in five of thirteen CI-deficient patient cell lines. Other beneficial effects of RSV include a decrease of total intracellular ROS and the up-regulation of the expression of mitochondrial superoxide dismutase (SOD2) protein, a key antioxidant defense enzyme. The molecular mechanisms leading to the up-regulation of SOD2 protein expression by RSV require the estrogen receptor (ER) and the estrogen-related receptor alpha (ERRα). Although RSV increases the level of SOD2 protein in patients’ fibroblasts, the enzyme activity is not increased, in contrast to normal fibroblasts. This led us to hypothesize that SOD2 enzyme activity is regulated post-translationally. This regulation involves SIRT3, a mitochondrial NAD + -dependent deacetylase and is critically dependent on NAD + levels. Taken together, our data show that the metabolic effects of RSV combined with its antioxidant capacities makes RSV particularly interesting as a candidate molecule for the therapy of CI deficiencies. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
44. Cellular prion protein dysfunction in a prototypical inherited metabolic myopathy
- Author
-
Johan Castille, Céline Tomkiewicz-Raulet, Fatima-Zohra Boufroura, Jean Bastin, Jean-Luc Vilotte, Fatima Djouadi, Virginie Poindessous, Sophie Mouillet-Richard, Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université de Paris (UP), Toxicité environnementale, cibles thérapeutiques, signalisation cellulaire (T3S - UMR_S 1124), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Génétique Animale et Biologie Intégrative (GABI), Université Paris-Saclay-AgroParisTech-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Association Française contre les Myopathies (AFM, Trampoline Grant 2016-2017) 19607, Institut National de la Sante et de la Recherche Medicale (Inserm), Djouadi, Fatima, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), and AgroParisTech-Université Paris-Saclay-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)
- Subjects
animal diseases ,[SDV]Life Sciences [q-bio] ,Muscle Fibers, Skeletal ,SOD2 ,Cellular prion protein ,Metabolic myopathy ,Prion Proteins ,Prion Diseases ,Focal adhesion ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,0302 clinical medicine ,Muscular Diseases ,medicine ,Animals ,Humans ,Carnitine ,Molecular Biology ,Beta oxidation ,Cells, Cultured ,Inherited metabolic myopathy ,030304 developmental biology ,Muscle differentiation ,Pharmacology ,Mice, Knockout ,0303 health sciences ,Carnitine O-Palmitoyltransferase ,Chemistry ,Myogenesis ,Superoxide Dismutase ,Cell Biology ,medicine.disease ,Cell biology ,Myotube differentiation ,nervous system diseases ,Inherited fatty acid oxidation disorders ,[SDV] Life Sciences [q-bio] ,Focal adhesions ,Molecular Medicine ,RNA Interference ,Myogenic Regulatory Factor 5 ,Oxidation-Reduction ,Redox balance ,030217 neurology & neurosurgery ,Function (biology) ,medicine.drug - Abstract
International audience; Inherited fatty acid oxidation diseases in their mild forms often present as metabolic myopathies. Carnitine Palmitoyl Transferase 2 (CPT2) deficiency, one such prototypical disorder is associated with compromised myotube differentiation. Here, we show that CPT2-deficient myotubes exhibit defects in focal adhesions and redox balance, exemplified by increased SOD2 expression. We document unprecedented alterations in the cellular prion protein PrPC, which directly arise from the failure in CPT2 enzymatic activity. We also demonstrate that the loss of PrPC function in normal myotubes recapitulates the defects in focal adhesion, redox balance and differentiation hallmarks monitored in CPT2-deficient cells. These results are further corroborated by studies performed in muscles from Prnp-/- mice. Altogether, our results unveil a molecular scenario, whereby PrPC dysfunction governed by faulty CPT2 activity may drive aberrant focal adhesion turnover and hinder proper myotube differentiation. Our study adds a novel facet to the involvement of PrPC in diverse physiopathological situations.
- Published
- 2020
45. Combination of lipid metabolism alterations and their sensitivity to inflammatory cytokines in human lipin-1-deficient myoblasts.
- Author
-
Michot, Caroline, Mamoune, Asmaa, Vamecq, Joseph, Viou, Mai Thao, Hsieh, Lu-Sheng, Testet, Eric, Lainé, Jeanne, Hubert, Laurence, Dessein, Anne-Frédérique, Fontaine, Monique, Ottolenghi, Chris, Fouillen, Laetitia, Nadra, Karim, Blanc, Etienne, Bastin, Jean, Candon, Sophie, Pende, Mario, Munnich, Arnold, Smahi, Asma, and Djouadi, Fatima
- Subjects
- *
LIPID metabolism , *INFLAMMATION , *CYTOKINES , *LIPIDS , *MYOBLASTS , *CARNITINE - Abstract
Abstract: Lipin-1 deficiency is associated with massive rhabdomyolysis episodes in humans, precipitated by febrile illnesses. Despite well-known roles of lipin-1 in lipid biosynthesis and transcriptional regulation, the pathogenic mechanisms leading to rhabdomyolysis remain unknown. Here we show that primary myoblasts from lipin-1-deficient patients exhibit a dramatic decrease in LPIN1 expression and phosphatidic acid phosphatase 1 activity, and a significant accumulation of lipid droplets (LD). The expression levels of LPIN1-target genes [peroxisome proliferator-activated receptors delta and alpha (PPARδ, PPARα), peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), acyl-coenzyme A dehydrogenase, very long (ACADVL), carnitine palmitoyltransferase IB and 2 (CPT1B and CPT2)] were not affected while lipin-2 protein level, a closely related member of the family, was increased. Microarray analysis of patients' myotubes identified 19 down-regulated and 51 up-regulated genes, indicating pleiotropic effects of lipin-1 deficiency. Special attention was paid to the up-regulated ACACB (acetyl-CoA carboxylase beta), a key enzyme in the fatty acid synthesis/oxidation balance. We demonstrated that overexpression of ACACB was associated with free fatty acid accumulation in patients' myoblasts whereas malonyl-carnitine (as a measure of malonyl-CoA) and CPT1 activity were in the normal range in basal conditions accordingly to the normal daily activity reported by the patients. Remarkably ACACB invalidation in patients' myoblasts decreased LD number and size while LPIN1 invalidation in controls induced LD accumulation. Further, pro-inflammatory treatments tumor necrosis factor alpha+Interleukin-1beta(TNF1α+IL-1ß) designed to mimic febrile illness, resulted in increased malonyl-carnitine levels, reduced CPT1 activity and enhanced LD accumulation, a phenomenon reversed by dexamethasone and TNFα or IL-1ß inhibitors. Our data suggest that the pathogenic mechanism of rhabdomyolysis in lipin-1-deficient patients combines the predisposing constitutive impairment of lipid metabolism and its exacerbation by pro-inflammatory cytokines. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
46. Low-Intensity Running and High-Intensity Swimming Exercises Differentially Improve Energy Metabolism in Mice With Mild Spinal Muscular Atrophy
- Author
-
Domenico D’Amico, Laure Weill, Valentin Rumeau, Thaïs Rouquet, Bruno Bariohay, Farah Chali, Cynthia Bezier, Céline Desseille, Julien Roux, Philippe Lopes, Léo Houdebine, Carole Oudot, Frédéric Charbonnier, Delphine Sapaly, Jean Bastin, Olivier Biondi, Judy Soukkari, Fatima Djouadi, Toxicité environnementale, cibles thérapeutiques, signalisation cellulaire (T3S - UMR_S 1124), Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Comportement nutritionnel et troubles métaboliques [La Penne-sur-Huveaune] (Biomeostasis CRO), Biomeostasis CRO [La Penne-sur-Huveaune], U.F.R. Sciences et Techniques des Activités Physiques et Sportives [Evry] (UFR STAPS - UEVE), Université d'Évry-Val-d'Essonne (UEVE), Sorbonne Université (SU), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), and Djouadi, Fatima
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Physiology ,[SDV]Life Sciences [q-bio] ,respiratory chain ,Respiratory chain ,Physical exercise ,030105 genetics & heredity ,Energy homeostasis ,lcsh:Physiology ,muscle mitochondria ,03 medical and health sciences ,0302 clinical medicine ,Lipid oxidation ,physical exercise ,Physiology (medical) ,Internal medicine ,energy metabolism ,medicine ,Glucose homeostasis ,Original Research ,lcsh:QP1-981 ,business.industry ,Lipid metabolism ,fat oxidation ,oxygen consumption ,3. Good health ,[SDV] Life Sciences [q-bio] ,Endocrinology ,Lipogenesis ,Spinal Muscular Atrophy ,business ,Anaerobic exercise ,030217 neurology & neurosurgery - Abstract
International audience; Spinal Muscular Atrophy (SMA), an autosomal recessive neurodegenerative disease characterized by the loss of spinal-cord motor-neurons, is caused by mutations on Survival-of-Motor Neuron (SMN)-1 gene. The expression of SMN2, a SMN1 gene copy, partially compensates for SMN1 disruption due to exon-7 excision in 90% of transcripts subsequently explaining the strong clinical heterogeneity. Several alterations in energy metabolism, like glucose intolerance and hyperlipidemia, have been reported in SMA at both systemic and cellular level, prompting questions about the potential role of energy homeostasis and/or production involvement in disease progression. In this context, we have recently reported the tolerance of mild SMA-like mice (SmnΔ7/Δ7; huSMN2 +/+) to 10 months of low-intensity running or high-intensity swimming exercise programs, respectively involving aerobic and a mix aerobic/anaerobic muscular metabolic pathways. Here, we investigated whether those exercise-induced benefits were associated with an improvement in metabolic status in mild SMA-like mice. We showed that untrained SMA-like mice exhibited a dysregulation of lipid metabolism with an enhancement of lipogenesis and adipocyte deposits when compared to control mice. Moreover, they displayed a high oxygen consumption and energy expenditure through β-oxidation increase yet for the same levels of spontaneous activity. Interestingly, both exercises significantly improved lipid metabolism and glucose homeostasis in SMA-like mice, and enhanced oxygen consumption efficiency with the maintenance of a high oxygen consumption for higher levels of spontaneous activity. Surprisingly, more significant effects were obtained with the high-intensity swimming protocol with the maintenance of high lipid oxidation. Finally, when combining electron microscopy, respiratory chain complexes expression and enzymatic activity measurements in muscle mitochondria, we found that (1) a muscle-specific decreased in enzymatic activity of respiratory chain I, II, and IV complexes for equal amount of mitochondria and complexes expression and (2) a significant decline in mitochondrial maximal oxygen consumption, were reduced by both exercise programs. Most of the beneficial effects were obtained with the high-intensity swimming protocol. Taking together, our data support the hypothesis that active physical exercise, including high-intensity protocols, induces metabolic adaptations at both systemic and cellular levels, providing further evidence for its use in association with SMN-overexpressing therapies, in the long-term care of SMA patients.
- Published
- 2019
47. A new AMPK activator, GSK773, corrects fatty acid oxidation and differentiation defect in CPT2-deficient myotubes
- Author
-
Carole Le Bachelier, Dimitri Schlemmer, Jean-François Benoist, Jean Bastin, Céline Tomkiewicz-Raulet, Yann Lamotte, Sophie Mouillet-Richard, Olivier Mirguet, Pascal Grondin, Fatima-Zohra Boufroura, Fatima Djouadi, Toxicité environnementale, cibles thérapeutiques, signalisation cellulaire (T3S - UMR_S 1124), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Service de biochimie-hormonologie, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Robert Debré-Université de Paris (UP), Laboratoires Oncodesign [Villebon-sur-Yvette], Centre de Recherches François Hyafil [Villebon-sur-Yvette], Institut de Recherches Internationales Servier [Suresnes] (IRIS), Médecine Personnalisée, Pharmacogénomique, Optimisation Thérapeutique (MEPPOT - U1147), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré-Université de Paris (UP), Djouadi, Fatima, Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré-Université Paris Cité (UPCité)
- Subjects
0301 basic medicine ,[SDV]Life Sciences [q-bio] ,Muscle Fibers, Skeletal ,Skeletal muscle adaptation ,Quinolones ,Biology ,Mitochondrion ,p38 Mitogen-Activated Protein Kinases ,Gene Expression Regulation, Enzymologic ,03 medical and health sciences ,0302 clinical medicine ,AMP-Activated Protein Kinase Kinases ,Myosin ,Genetics ,Humans ,Myocyte ,PPAR alpha ,RNA, Small Interfering ,Muscle, Skeletal ,Molecular Biology ,Genetics (clinical) ,Carnitine O-Palmitoyltransferase ,Myosin Heavy Chains ,Myogenesis ,Fatty Acids ,AMPK ,General Medicine ,Lipid Metabolism ,Cell biology ,[SDV] Life Sciences [q-bio] ,030104 developmental biology ,mitochondrial fusion ,Mitochondrial biogenesis ,Mutation ,Reactive Oxygen Species ,Protein Kinases ,Metabolism, Inborn Errors ,030217 neurology & neurosurgery - Abstract
International audience; Carnitine palmitoyl transferase 2 (CPT2) deficiency is one of the most common inherited fatty acid oxidation (FAO) defects and represents a prototypical mitochondrial metabolic myopathy. Recent studies have suggested a pivotal role of adenosine monophosphate-activated protein kinase (AMPK) in skeletal muscle plasticity and mitochondrial homeostasis. Thus, we tested the potential of GSK773, a novel direct AMPK activator, to improve or correct FAO capacities in muscle cells from patients harboring various mutations. We used controls' and patients' myotubes and studied the parameters of FAO metabolism, of mitochondrial quantity and quality and of differentiation. We found that AMPK is constitutively activated in patients' myotubes, which exhibit both reduced FAO and impaired differentiation. GSK773 improves or corrects several metabolic hallmarks of CPT2 deficiency (deficient FAO flux and C16-acylcarnitine accumulation) by upregulating the expression of CPT2 protein. Beneficial effects of GSK773 are also likely due to stimulation of mitochondrial biogenesis and induction of mitochondrial fusion, by decreasing dynamin-related protein 1 and increasing mitofusin 2. GSK773 also induces a shift in myosin heavy chain isoforms toward the slow oxidative type and, therefore, fully corrects the differentiation process. We establish, through small interfering RNA knockdowns and pharmacological approaches, that these GSK773 effects are mediated through peroxisome proliferator-activated receptor gamma co-activator 1-alpha, reactive oxygen species and p38 mitogen-activated protein kinase, all key players of skeletal muscle plasticity. GSK773 recapitulates several important features of skeletal muscle adaptation to exercise. The results show that AMPK activation by GSK773 evokes the slow, oxidative myogenic program and triggers beneficial phenotypic adaptations in FAO-deficient myotubes. Thus, GSK773 might have therapeutic potential for correction of CPT2 deficiency.
- Published
- 2018
48. Resveratrol attenuates oxidative stress in mitochondrial Complex I deficiency: Involvement of SIRT3
- Author
-
Robert W. Taylor, Lise Mathieu, Carole Le Bachelier, Abdelhamid Slama, Jean Bastin, Anne-Sophie Lebre, Fatima Djouadi, Alexandra Lopes Costa, Toxicité environnementale, cibles thérapeutiques, signalisation cellulaire (T3S - UMR_S 1124), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Service de Biochimie [AP-HP Hôpital Bicêtre], AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Service de génétique [Reims], Centre Hospitalier Universitaire de Reims (CHU Reims), Wellcome Trust Centre for Mitochondrial Research [Newcastle upon Tyne, UK] (Institute of Genetic Medicine), Newcastle University [Newcastle]-International Centre for Life, Djouadi, Fatima, Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP)
- Subjects
0301 basic medicine ,SIRT3 ,[SDV]Life Sciences [q-bio] ,SOD2 ,Mitochondrial diseases ,Mitochondrion ,Pharmacology ,Resveratrol ,Biology ,Biochemistry ,Antioxidants ,Superoxide dismutase ,03 medical and health sciences ,chemistry.chemical_compound ,Oxygen Consumption ,Physiology (medical) ,Sirtuin 3 ,Stilbenes ,Humans ,Cells, Cultured ,chemistry.chemical_classification ,Reactive oxygen species ,Electron Transport Complex I ,Superoxide Dismutase ,Key terms: Complex I deficiency ,Estrogen Receptor alpha ,Pharmacological therapy ,Complex I deficiency ,Fibroblasts ,3. Good health ,Mitochondria ,[SDV] Life Sciences [q-bio] ,030104 developmental biology ,chemistry ,Gene Expression Regulation ,Receptors, Estrogen ,Oxidative stress ,biology.protein ,NAD+ kinase ,Signal transduction ,Reactive Oxygen Species ,Signal Transduction - Abstract
International audience; The pathophysiological mechanisms underlying Complex I (CI) deficiencies are understood only partially which severely limits the treatment of this common, devastating, mitochondrial disorder. Recently, we have shown that resveratrol (RSV), a natural polyphenol, has beneficial effects on CI deficiency of nuclear origin. Here, we demonstrate that RSV is able to correct the biochemical defect in oxygen consumption in five of thirteen CI-deficient patient cell lines. Other beneficial effects of RSV include a decrease of total intracellular ROS and the up-regulation of the expression of mitochondrial superoxide dismutase (SOD2) protein, a key antioxidant defense enzyme. The molecular mechanisms leading to the up-regulation of SOD2 protein expression by RSV require the estrogen receptor (ER) and the estrogen-related receptor alpha (ERRα). Although RSV increases the level of SOD2 protein in patients' fibroblasts, the enzyme activity is not increased, in contrast to normal fibroblasts. This led us to hypothesize that SOD2 enzyme activity is regulated post-translationally. This regulation involves SIRT3, a mitochondrial NAD þ-dependent deacetylase and is critically dependent on NAD þ levels. Taken together, our data show that the metabolic effects of RSV combined with its antioxidant capacities makes RSV particularly interesting as a candidate molecule for the therapy of CI deficiencies.
- Published
- 2016
49. Stilbenes and resveratrol metabolites improve mitochondrial fatty acid oxidation defects in human fibroblasts
- Author
-
Fatima Djouadi, Dimitri Schlemmer, Jean-François Benoist, Carole Le Bachelier, Norbert Latruffe, Jean Bastin, Virginie Aires, Dominique Delmas, Université Bourgogne Franche-Comté [COMUE] (UBFC), Laboratoire Bio-PeroxIL. Biochimie du Peroxysome, Inflammation et Métabolisme Lipidique (Bio-PeroxIL), Université de Bourgogne (UB), Lipides - Nutrition - Cancer (U866) (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA), Toxicité environnementale, cibles thérapeutiques, signalisation cellulaire (T3S - UMR_S 1124), Université Paris Descartes - Paris 5 (UPD5)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de biochimie-hormonologie, Université de Paris (UP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré, Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré-Université Paris Cité (UPCité), and Djouadi, Fatima
- Subjects
[SDV]Life Sciences [q-bio] ,Blotting, Western ,Stimulation ,Mitochondrion ,Resveratrol ,Biology ,Pharmacology ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,In vivo ,Stilbenes ,medicine ,Humans ,Genetics(clinical) ,Pharmacology (medical) ,Carnitine ,Patient fibroblasts ,Genetics (clinical) ,030304 developmental biology ,Piceid ,EC50 ,Medicine(all) ,chemistry.chemical_classification ,0303 health sciences ,Research ,Fatty Acids ,food and beverages ,Mitochondrial FAO defects ,Pharmacological therapy ,General Medicine ,Fibroblasts ,Mitochondria ,3. Good health ,[SDV] Life Sciences [q-bio] ,Enzyme ,chemistry ,Oxidation-Reduction ,030217 neurology & neurosurgery ,medicine.drug - Abstract
International audience; Background: Inborn enzyme defects of mitochondrial fatty acid beta-oxidation (FAO) form a large group of genetic disorders associated to variable clinical presentations ranging from life-threatening pediatric manifestations up to milder late onset phenotypes, including myopathy. Very few candidate drugs have been identified in this group of disorders. Resveratrol (RSV) is a natural polyphenol with anti-oxidant and anti-inflammatory effects, recently shown to have beneficial metabolic properties in mice models. Our study explores its possible effects on FAO and mitochondrial energy metabolism in human cells, which are still very little documented.Methods: Using cells from controls and from patients with Carnitine Palmitoyl Transferase 2 (CPT2) or Very Long Chain AcylCoA Dehydrogenase (VLCAD) deficiency we characterized the metabolic effects of RSV, RSV metabolites, and other stilbenes. We also focused on analysis of RSV uptake, and on the effects of low RSV concentrations, considering the limited bioavailability of RSV in vivo.Results: Time course of RSV accumulation in fibroblasts over 48 h of treatment were consistent with the resulting stimulation or correction of FAO capacities. At 48 h, half maximal and maximal FAO stimulations were respectively achieved for 37,5 microM (EC50) and 75 microM RSV, but we found that serum content of culture medium negatively modulated RSV uptake and FAO induction. Indeed, decreasing serum from 12% to 3% led to shift EC50 from 37,5 to 13 microM, and a 2.6-3.6-fold FAO stimulation was reached with 20 microM RSV at 3% serum, that was absent at 12% serum. Two other stilbenes often found associated with RSV, i.e. cis- RSV and piceid, also triggered significant FAO up-regulation. Resveratrol glucuro- or sulfo- conjugates had modest or no effects. In contrast, dihydro-RSV, one of the most abundant circulating RSV metabolites in human significantly stimulated FAO (1.3-2.3-fold).Conclusions: This study provides the first compared data on mitochondrial effects of resveratrol, its metabolites, and other natural compounds of the stilbene family in human cells. The results clearly indicate that several of these compounds can improve mitochondrial FAO capacities in human FAO-deficient cells.
- Published
- 2014
50. Mitochondrial trifunctional protein deficiency in human cultured fibroblasts : effects of bezafibrate
- Author
-
Simon E. Olpin, Pascale de Lonlay, A. Boutron, Dimitri Schlemmer, Sacha Ferdinandusse, Carole Le Bachelier, J.F. Benoist, Toshiyuki Fukao, Jean Bastin, Seiji Yamaguchi, Brage S. Andresen, Ronald J.A. Wanders, Florence Habarou, Arnold W. Strauss, Fatima Djouadi, Gepke Visser, Djouadi, Fatima, Toxicité environnementale, cibles thérapeutiques, signalisation cellulaire (T3S - UMR_S 1124), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Laboratory Genetic Metabolic Diseases [Academic Medical Centre], Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA)-University of Amsterdam [Amsterdam] (UvA), Centre Référence des Maladies Héréditaires du Métabolisme [Paris-Robert Debré], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré-Service de neurologie, maladies métaboliques, Département de Biochimie [AP-HP Hôpital Robert Debré], AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Biochimie [AP-HP Hôpital Bicêtre], AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), University of Southern Denmark (SDU), Wilhelmina Children's Hospital [Utrecht, The Netherlands], University Medical Center [Utrecht], Génétique et épigénétique des maladies métaboliques, neurosensorielles et du développement (Inserm U781), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Sheffield Children's NHS Foundation Trust, Gifu University Graduate School of Medicine, Shimane University, Cincinnati Children's Hospital Medical Center, Amsterdam Gastroenterology Endocrinology Metabolism, Laboratory Genetic Metabolic Diseases, and Université Paris Descartes - Paris 5 (UPD5)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
0301 basic medicine ,Genotype ,[SDV]Life Sciences [q-bio] ,Alpha (ethology) ,Mitochondrial trifunctional protein deficiency ,Mitochondrial trifunctional protein ,Biology ,medicine.disease_cause ,Research Support ,Lipid Metabolism, Inborn Errors ,Rhabdomyolysis ,Cell Line ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Genetics ,Journal Article ,Humans ,Genetics(clinical) ,Non-U.S. Gov't ,Beta oxidation ,Genetics (clinical) ,G alpha subunit ,Hypolipidemic Agents ,Mutation ,Bezafibrate ,Mitochondrial Trifunctional Protein ,Research Support, Non-U.S. Gov't ,Mitochondrial Myopathies ,Fibroblasts ,medicine.disease ,Molecular biology ,3. Good health ,[SDV] Life Sciences [q-bio] ,030104 developmental biology ,Biochemistry ,Mitochondrial Trifunctional Protein, beta Subunit ,biology.protein ,Mitochondrial Trifunctional Protein, alpha Subunit ,Nervous System Diseases ,Cardiomyopathies ,030217 neurology & neurosurgery ,HADHB ,medicine.drug - Abstract
International audience; Mitochondrial trifunctional protein (MTP) deficiency caused by HADHA or HADHB gene mutations exhibits substantial molecular, biochemical, and clinical heterogeneity and ranks among the more severe fatty acid oxidation (FAO) disorders, without pharmacological treatment. Since bezafibrate has been shown to potentially correct other FAO disorders in patient cells, we analyzed its effects in 26 MTP-deficient patient fibroblasts representing 16 genotypes. Overall, the patient cell lines exhibited variable, complex, biochemical profiles and pharmacological responses. HADHA-deficient fibroblasts showed markedly reduced alpha subunit protein levels together with decreased beta-subunit abundance, exhibited a -86 to -96% defect in LCHAD activity, and produced large amounts of C14 and C16 hydroxyacylcarnitines. In control fibroblasts, exposure to bezafibrate (400 μM for 48 h) increased the abundance of HADHA and HADHB mRNAs, immune-detectable alpha and beta subunit proteins, activities of LCHAD and LCKAT, and stimulated FAO capacities, clearly indicating that MTP is pharmacologically up-regulated by bezafibrate in human fibroblasts. In MTP-deficient patient fibroblasts, which were found markedly FAO-deficient, bezafibrate improved FAO capacities in six of 26 (23%) cases, including three cell lines heterozygous for the common c1528G > C mutation. Altogether, our results strongly suggest that, due to variable effects of HADHA and HADHB mutations on MTP abundance and residual activity, improvement of MTP deficiency in response to bezafibrate was achieved in a subset of responsive genotypes.
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.